Multiple sclerosis (MS) is a costly disease for society, because it affects young people and has a relentless course with progressive accumulation of physical disability and cognitive deficits. MS is expensive not only because of the high prices of available treatments, but also because of reduced employment/job retention for patients and their caregivers. This is especially true for patients with disease onset during childhood, who usually reach more severe disability at a younger age than those with adult-onset MS.